Clinical trials: Retinal Vascularisation
Age-Related Macular Degeneration, Choroidal Neovascularization
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
- Trial name
- 20089/Combo (NCT01175395)
- Testing
- IBI-20089/Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Diabetic Retinopathy, Myopia
OCTA Metrics Repeatability and Reproducibility in Different Disorders
Retinal imaging is a corner stone in diagnosis of most retinal disorders. Standard imaging techniques e.g. fluorescein angiography and color fundus photography have a lot of limitations including limited resolution, invasive…
- Conditions
- Diabetic Retinopathy, Myopia, Choroidal Neovascularization, Healthy
- Trial name
- NCT04488887
- Testing
- Optical coherence tomography angiography
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
- Trial name
- NCT00857259
- Testing
- Everolimus, Ranibizumab
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Combretastatin A4 Phosphate, Age-related Macular Degeneration
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration
- Conditions
- Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV
- Trial name
- NCT01570790
- Testing
- Combretastatin A-4 phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration, Choroidal Neovascularization
Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
- Trial name
- NCT00102115
- Testing
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Light Sciences LLC
Macular Degeneration
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2.
- Trial name
- NCT02228304
- Testing
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Where
- 38 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Neurotech Pharmaceuticals
Age Related Macular Degeneration
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular…
- Trial name
- NCT00556348
- Testing
- bevacizumab
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Edema, Central Serous Chorioretinopathy
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Laser photocoagulation of the retina targeting the outer layers is an established therapy for proliferative retinopathy and macular edema from diabetic microangiopathy or retinal vein occlusion, centrals serous retinopathy, and…
- Conditions
- Macular Edema, Central Serous Chorioretinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
- Trial name
- NCT02088151
- Testing
- Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Retinopathy of Prematurity
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
The aim of the present study is to evaluate the safety and efficacy of propranolol eye drops in preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- DROP-PROP (NCT02014454)
- Testing
- Propranolol eye drops
- Where
- 2 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Meyer Children's Hospital IRCCS
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration, Wet Macular Degeneration
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to confirm the clinical and economic benefits of IRay treatment with respect to the number of anti-VEGF injections and frequency of visits during the first year after treatment for patients with wet…
- Conditions
- Age-Related Macular Degeneration, Wet Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- ENDEAVOUR (NCT01521065)
- Testing
- IRay
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Oraya Therapeutics, Inc.
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or…
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Trial name
- NCT01011374
- Testing
- ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Cleveland, Inc
Macular Degeneration
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- CABERNET (NCT00454389)
- Testing
- Epi-Rad90™ Ophthalmic System, ranibizumab
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 494 people
- Sponsor
- NeoVista